1. Taiwan, Province of China Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Advagene Biopharma Co., Ltd.

Advagene Biopharma Co., Ltd.

6709.TWO
Advagene Biopharma Co., Ltd.TW flagTaipei Exchange
25.30
TWD
+0.30
- -
1.73BMarket Cap
Advagene Biopharma Co., Ltd.
6709.TWO
(Taipei Exchange)

Recent

price

25.30

P/E

ratio

- -

div

yld

- -

ROIC.AI

2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
-4
-4.69
-3.1
-2.05
-1.57
-1.88
-2.4
-1.73
-1.27
- -
Basic EPS, GAAP
-6.43
-6.3
-1.11
-0.94
-0.7
-1.38
-2.42
-1.46
-1.3
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
2.67
2.46
4.98
4.27
6.58
3.14
2.61
1.49
2.39
- -
Book Value per Share
5.58
6.57
9.21
5.67
6.39
4.89
2.47
2.62
4.03
- -
Tangible Book Value per Share
23
29
36
45
45
49
49
53
55
- -
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
3
4
5
7
8
8
12
12
2
2
Depreciation Expense
-91
-138
-111
-92
-70
-93
-118
-92
-69
-68
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
120
188
326
249
282
236
117
138
218
147
Working Capital
- -
- -
- -
- -
4
3
1
- -
5
3
LT Debt
141
214
347
271
299
250
132
140
221
152
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
-207.42
-88.59
-49.62
-28.95
-41.31
-83.63
-88.48
-66.08
-48.3
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-6.2%
-30.96%
Free Cash Flow
- -
28.05%
-7.71%
Net Income, GAAP
- -
2.27%
-1.63%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-1.73
2024
- -
- -
- -
- -
-1.27
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
Alaunos Therapeutics, Inc. (TCRT)
Seres Therapeutics, Inc. (MCRB)
DMS Imaging S.A. (ASIT.BR)
Purple Biotech Ltd. (PPBT)
2cureX AB (publ) (2CUREX.ST)
Synbio Tech Inc. (1295.TWO)
Business
Advagene Biopharma Co., Ltd. (6709.TWO) develops and manufactures gene therapy vectors and related biopharmaceutical products for treating genetic and chronic diseases. The company offers adeno-associated virus (AAV) vectors, including AAV2, AAV5, AAV8, and AAV9 serotypes customized for specific therapeutic applications; plasmid DNA production services; and viral vector packaging platforms for research, preclinical, and clinical use. Its product portfolio encompasses GMP-grade viral vectors, helper plasmids, and cell lines such as HEK293 for gene delivery systems targeting ophthalmology, neurology, and oncology indications. Advagene operates primarily in Taiwan and Asia-Pacific markets, serving pharmaceutical companies, contract development and manufacturing organizations (CDMOs), and academic institutions. Founded in 2016 and headquartered in Taipei, Taiwan, the company recently expanded its production capacity through a new GMP facility in 2024 to meet growing demand for high-titer AAV vectors; formed a strategic manufacturing partnership with a leading U.S. biotech firm in early 2025 for co-development of retinal disease therapies; and launched an enhanced AAV9-based platform for central nervous system disorders following successful preclinical data reported in late 2024. No subsidiaries or parent entities are reported.